AR067666A1 - Proteinas de union al antigeno del receptor de il-18 - Google Patents

Proteinas de union al antigeno del receptor de il-18

Info

Publication number
AR067666A1
AR067666A1 ARP080103206A ARP080103206A AR067666A1 AR 067666 A1 AR067666 A1 AR 067666A1 AR P080103206 A ARP080103206 A AR P080103206A AR P080103206 A ARP080103206 A AR P080103206A AR 067666 A1 AR067666 A1 AR 067666A1
Authority
AR
Argentina
Prior art keywords
proteins
union
antigen
receiver
antigen binding
Prior art date
Application number
ARP080103206A
Other languages
English (en)
Spanish (es)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR067666A1 publication Critical patent/AR067666A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
ARP080103206A 2007-07-24 2008-07-24 Proteinas de union al antigeno del receptor de il-18 AR067666A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95169207P 2007-07-24 2007-07-24
US95169107P 2007-07-24 2007-07-24
US7314208P 2008-06-17 2008-06-17

Publications (1)

Publication Number Publication Date
AR067666A1 true AR067666A1 (es) 2009-10-21

Family

ID=40282148

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103206A AR067666A1 (es) 2007-07-24 2008-07-24 Proteinas de union al antigeno del receptor de il-18

Country Status (17)

Country Link
US (3) US8257707B2 (enExample)
EP (1) EP2178917A4 (enExample)
JP (2) JP2010534478A (enExample)
KR (1) KR20100049535A (enExample)
CN (1) CN101835489B (enExample)
AR (1) AR067666A1 (enExample)
AU (1) AU2008279127B2 (enExample)
BR (1) BRPI0813016A2 (enExample)
CA (1) CA2693503A1 (enExample)
CL (1) CL2008002153A1 (enExample)
EA (1) EA016783B1 (enExample)
IL (1) IL202833A0 (enExample)
PE (1) PE20090518A1 (enExample)
SG (1) SG183070A1 (enExample)
TW (1) TWI436778B (enExample)
WO (1) WO2009015284A2 (enExample)
ZA (1) ZA201001140B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AR082518A1 (es) 2010-08-25 2012-12-12 Hoffmann La Roche Anticuerpos contra il-18r1 y usos de los mismos
SG10202006507XA (en) 2012-05-30 2020-08-28 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule
US8821242B2 (en) 2012-07-25 2014-09-02 Lumos Labs, Inc. Systems and methods for enhancing cognition
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
KR102085179B1 (ko) * 2013-05-07 2020-04-16 삼성전자주식회사 디바이스의 위치에 기초한 콘텐트 제공 시스템 및 방법
CA2923145C (en) 2013-09-05 2025-09-16 Amgen Inc. MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
AU2014358191B2 (en) 2013-12-04 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
MX377275B (es) 2014-05-16 2025-03-07 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
US10792100B2 (en) 2014-08-20 2020-10-06 Covidien Lp Systems and methods for spherical ablations
KR20160047889A (ko) * 2014-10-23 2016-05-03 삼성전자주식회사 전자 장치 및 피공유자 추천 서비스 운용 방법
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN119639849A (zh) 2018-03-26 2025-03-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
WO2019242655A1 (en) * 2018-06-19 2019-12-26 Shanghaitech University Human antibodies to human interleukin 18 receptor alpha and beta
PT3618928T (pt) 2018-07-13 2023-03-29 Alector Llc Anticorpos anti-sortilina e métodos de utilização dos mesmos
IL317002A (en) 2018-08-10 2025-01-01 Chugai Pharmaceutical Co Ltd Anti-CD137 antigen binding molecule and use thereof
AU2020355251A1 (en) 2019-09-26 2022-04-21 Amgen Inc. Methods of producing antibody compositions
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
CN114736291B (zh) * 2021-01-07 2023-08-11 中国科学院微生物研究所 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023134767A1 (zh) * 2022-01-14 2023-07-20 和径医药科技（上海）有限公司 一种靶向IL-18Rβ的抗体及其应用
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2026090253A1 (en) 2024-10-23 2026-04-30 Amgen Inc. Methods of determining glycan pairing content

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776731A (en) 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
AU750767B2 (en) 1998-01-23 2002-07-25 Immunex Corporation ACPL DNA and polypeptides
ATE272114T1 (de) 1998-01-23 2004-08-15 Immunex Corp Rezeptoren für il-18
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
IL131047A0 (en) 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
AU7676300A (en) 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
PL356836A1 (en) 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
AU2001268427B2 (en) * 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
CA2422881A1 (en) 2000-10-13 2002-04-18 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
AU2002224417A1 (en) 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
CN100556450C (zh) 2001-05-16 2009-11-04 耶达研究发展有限公司 Il-18抑制剂在治疗或预防脓毒症中的应用
US20040023336A1 (en) * 2001-10-26 2004-02-05 Heavner George A. Mut-IL-18 or Mut-IL-18R proteins, antibodies, compositions, methods and uses
EP1461082A4 (en) * 2001-12-03 2006-06-28 Abgenix Inc ANTIBODIES AGAINST THE TUMOR ANTIGEN OF CARBON IX ANHYDRASE (CA IX)
CN100558895C (zh) * 2003-07-18 2009-11-11 持田制药株式会社 抗血小板膜糖蛋白vi单克隆抗体
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP1808446B1 (en) * 2004-07-16 2012-01-18 Atsuo Sekiyama Il-18 receptor antagonist and pharmaceutical composition containing the antagonist

Also Published As

Publication number Publication date
WO2009015284A3 (en) 2009-10-01
CL2008002153A1 (es) 2009-06-05
EA201000238A1 (ru) 2010-08-30
TWI436778B (zh) 2014-05-11
IL202833A0 (en) 2011-08-01
AU2008279127A1 (en) 2009-01-29
JP2010534478A (ja) 2010-11-11
EP2178917A2 (en) 2010-04-28
JP2015015957A (ja) 2015-01-29
CN101835489A (zh) 2010-09-15
US8540993B2 (en) 2013-09-24
KR20100049535A (ko) 2010-05-12
AU2008279127B2 (en) 2014-03-27
EA016783B1 (ru) 2012-07-30
US20140093915A1 (en) 2014-04-03
CA2693503A1 (en) 2009-01-29
US20130034569A1 (en) 2013-02-07
US8257707B2 (en) 2012-09-04
EP2178917A4 (en) 2012-03-28
WO2009015284A2 (en) 2009-01-29
WO2009015284A8 (en) 2009-07-02
SG183070A1 (en) 2012-08-30
BRPI0813016A2 (pt) 2015-12-15
ZA201001140B (en) 2011-03-30
PE20090518A1 (es) 2009-04-25
US20110014201A1 (en) 2011-01-20
TW200927167A (en) 2009-07-01
CN101835489B (zh) 2013-10-16

Similar Documents

Publication Publication Date Title
EA201000238A1 (ru) Антигенсвязывающие белки для il-18 рецептора и их применение
SA520420658B1 (ar) جزيئات ربط ضد bcma واستخداماتها
MX369334B (es) Moleculas de union al dominio de fibronectina de tipo iii del receptor del factor de crecimiento epidermico y del receptor del factor de crecimiento de hepatocitos (egfr y c-met).
CL2018001971A1 (es) Ror1 composiciones de anticuerpos y métodos relacionados
PE20151146A1 (es) Proteinas de union al antigeno bcma
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
BR112013031892A2 (pt) anticorpos anti-psgl-1 e seu uso
AR054539A1 (es) Nuevos anticuerpos anti- madcam
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
GT201000148A (es) Anticuerpos antimesotelina y usos de los mismos
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
BR112015014751A2 (pt) anticorpos anti-tau humanos
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
AR088941A1 (es) Anticuerpos anti-fgfr2 y sus usos
CO6571881A2 (es) Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
NI201200080A (es) Antagonistas de il-17a
AR073072A1 (es) Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
CR11042A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
CO7250445A2 (es) Proteínas de unión a antígeno st2
CR20110400A (es) Proteinas de enlace al receptor cgrp humano
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
CU20120116A7 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5

Legal Events

Date Code Title Description
FA Abandonment or withdrawal